An intronic deletion polymorphism that produces a less active form of BIM in chronic myeloid leukemia and lung adenocarcinoma patients leads to therapeutic resistance to tyrosine kinase inhibitors [14, 18]. The gene discussed is BCL2L11; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.